Concepedia

Catherine Vandenplas

CV

Statistics

Publications

11

Citations

600

H-Index

11

Active since

1996

Affiliations

UCB Pharma (Belgium)(Current)

UCLouvain

University of Liège

Mario Negri Institute for Pharmacological Research

Catherine Vandenplas is an author at UCB Pharma (Belgium) specializing in medicine, pharmacology, and biochemistry.

Top concepts

Publications per year

1996–2019

11

Publications

11

A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

Prashant K. Srivastava, Jonathan van Eyll, Patrice Godard et al. · Nature Communications · 2018 · 102 citations · Full text

n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis

Federica Frigerio, Giulia Pasqualini, Ilaria Craparotta et al. · Brain · 2018 · 92 citations · Full text

, , +25

Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation

Isabelle Niespodziany, Nathalie Leclère, Catherine Vandenplas et al. · Journal of Neuroscience Research · 2012 · 70 citations

Expression pattern of synaptic vesicle protein 2 (<scp>SV</scp>2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis

Julie Crèvecœur, R. M. Kaminski, Bernard Rogister et al. · Neuropathology and Applied Neurobiology · 2013 · 69 citations

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

Jean‐Pierre Desager, Yves Horsmans, Catherine Vandenplas et al. · Atherosclerosis · 1996 · 55 citations

, , +6

1–5 of 11